Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
This study has been completed.
Study NCT01288209 Information provided by Janssen Pharmaceutical K.K.
First Received on February 1, 2011. Last Updated on December 18, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
More general conditions related to this trial
Digestive System Diseases
Hepatitis, Viral, Human
RNA Virus Infections
Interventions listed in this trial
Peginterferon alfa-2a (PegIFNα-2a )
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Janssen Pharmaceutical K.K.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers